AAA
JBIO icon

Affinity Asset Advisors’s Jade Biosciences JBIO Stock Holding History

Affinity Asset Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
840,350
+200,394
+31% +$4.18M 0.84% 37
2026
Q1 		$8.99M Sell
639,956
-75,000
-10% -$1.09M 0.46% 54
2025
Q4 		$11M Buy
714,956
+649,639
+995% +$7.62M 0.63% 43
2025
Q3 		$564K Hold
65,317
– – 0.05% 88
2025
Q2 		$653K Buy
65,317
+42,460
+186% +$1.45M 0.09% 76
2025
Q1 		$2.01M Hold
22,857
– – 0.19% 67
2024
Q4 		$2.12M Buy
22,857
+5,714
+33% +$492K 0.28% 57
2024
Q3 		$1.25M Buy
17,143
+11,429
+200% +$737K 0.17% 70
2024
Q2 		$332K Buy
+5,714
New +$3.79M 0.04% 92

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Affinity Asset Advisors's JBIO Position: Q2 2026 in Review

Affinity Asset Advisors increased its Jade Biosciences (JBIO) stake by 31% in Q2 2026, buying an estimated $4.18M and bringing the position to 840,350 shares worth $18.7M. The position accounts for 0.84% of the portfolio, ranked #37.

Affinity Asset Advisors first reported a position in JBIO in Q2 2024 and has held it in 9 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Affinity Asset Advisors held 840,350 shares of Jade Biosciences worth $18.7M as of Q2 2026.
  • Affinity Asset Advisors bought 200,394 Jade Biosciences shares in Q2 2026, an estimated $4.18M.
  • Jade Biosciences made up 0.84% of Affinity Asset Advisors's portfolio in Q2 2026, its #37 holding.
  • Affinity Asset Advisors first reported a position in Jade Biosciences in Q2 2024 and has held it in 9 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.